Ionis Pharmaceuticals Inc. Watch

from 10-Q 122 pages Certain Portions of This Exhibit, Marked by [***], Have Been Excluded Because They Are Both Not Material and Are the Type That the Registrant Treats as Private or Confidential. Amended and Restated License Agreement by and Between Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. Dated June 18, 2024

from 10-Q 6 pages Second Amendment to Amended and Restated Lease

from 10-Q 9 pages Terms of Advisory Agreement

from 10-K 109 pages License Agreement by and Between Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. Dated December 15, 2023

from 10-K 6 pages First Amendment to Amended and Restated Lease

from 10-K 7 pages Indemnity Agreement

from 10-Q 97 pages Research, Development, and License Agreement Among Ionis Pharmaceuticals, Inc., and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc

from 10-Q 149 pages Amended and Restated Lease Agreement Dated as of August 21, 2023 Between Lots 21 & 22 Owner (De) LLC a Delaware Limited Liability Company as Landlord and Ionis Pharmaceuticals, Inc., a Delaware Corporation as Tenant Basic Lease Information

from 10-Q 95 pages Collaboration and License Agreement Between Ionis Pharmaceuticals, Inc. and Novartis Pharma AG Collaboration and License Agreement

from 10-Q 3 pages Certain Portions of This Exhibit, Marked by [***], Have Been Excluded Because They Are Both Not Material and Are the Type That the Registrant Treats as Private or Confidential. Confidential June 29, 2023 Astrazeneca Ab Se-431 83 Mölndal Gothenburg, Sweden Attention: Kajsa Lundqvist Re: Collaboration and License Agreement Dated December 6, 2021, by and Between Akcea Therapeutics, Inc. (“Akcea”) and Astrazeneca Ab

from 10-Q 3 pages First Amendment to Purchase and Sale Agreement

from 10-Q 5 pages Amendment No. 3 to Collaboration and License Agreement

from 10-Q 107 pages Certain Portions of This Exhibit, Marked by [***], Have Been Excluded Because They Are Both Not Material and Are the Type That the Registrant Treats as Private or Confidential Htt Research, Development, Option and License Agreement Among ISIS Pharmaceuticals, Inc., and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Htt Research, Development, Option and License Agreement

from 10-Q 9 pages Ionis Pharmaceuticals, Inc. Restricted Stock Unit Grant Notice

from 10-Q 15 pages Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors’ Stock Option Plan Adopted by the Board of Directors September 11, 2001 Approved by Stockholders May 31, 2002 Effective Date: May 31, 2002 Amended: April 20, 2006 (Amendment Approved by Board on December 12, 2005 and April 20, 2006 and by the Stockholders on May 3, 2006) Amended: June 5, 2008 (Amendment Approved by Board on September 13, 2007 and February 22, 2008 and by the Stockholders on June 5, 2008) Amended and Restated: June 2, 2010 (Amendment and Restatement Approved by Board on February 26, 2010 and by the Stockholders on June 2, 2010) Amended and Restated: June 7, 2012 (Amendment and Restatement Approved by Board on March 27, 2012 and by the Stockholders on June 7, 2012) Amended and Restated: June 10, 2014 (Amendment and Restatement Approved by Board on February 11, 2014 and by the Stockholders on June 10, 2014) Amended and Restated: June 30, 2015 (Amendment and Restatement Approved by Board on March 20, 2015 and by the Stockholders on June 30, 2015) Amended and Restated: June 4, 2020 (Amendment and Restatement Approved by Board on March 24, 2020 and by the Stockholders on June 4, 2020) Amended: March 14, 2023

from 10-Q 2 pages Second Amended Non-Employee Director Compensation Policy as of April 24, 2023

from 10-K 57 pages Royalty Purchase Agreement by and Between Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. (For the Limited Purposes Set Forth Herein) and Royalty Pharma Investments 2019 Icav Dated as of January 9, 2023

from 10-K 112 pages Collaboration and License Agreement Between Metagenomi, Inc. and Ionis Pharmaceuticals, Inc. Dated November 10, 2022

from 10-K 20 pages Defeasance Account Agreement

from 10-K 19 pages Defeasance Assignment, Assumption and Release Agreement